Combination treatment of hiv infections
AssigneeDebiopharm International S.A.
InventorsGrégoire Vuagniaux, Norbert Wiedemann
Life of this patent
Estimating the term…
Abstract
The present invention provides combination therapies for the treatment of HIV. The combination therapies of the present invention are aimed to reverse HIV latency and ultimately cure the disease. The combination therapies of the invention involve the use of an IAP inhibitor and the use of an immune checkpoint inhibitor.
Claims23
-18. (canceled)
A pharmaceutical composition comprising an IAP inhibitor and an immune checkpoint inhibitor, wherein the IAP inhibitor is preferably selected from Debio 1143, Debio 1143 analogues, LCL-161, TL-32711/birinapant, CUDC 427/GDC 0917, APG-1387, ASTX660, SBP-0636457, JP1201, AZD5582, and BI 891065 and the immune checkpoint inhibitor is preferably selected from the group consisting of CTLA-4 antagonists, PD-1 inhibitors, LAG-3 inhibitors, TIGIT inhibitors, Tim-3 inhibitors and PDL-1 inhibitors.
(canceled)
(canceled)
A method of treatment of HIV infection in a patient in need thereof, said method comprising administering to the patient the IAP inhibitor together with an immune checkpoint inhibitor, wherein the IAP inhibitor is preferably selected from Debio 1143, LCL-161, TL-32711/birinapant, CUDC 427/GDC 0917, APG-1387, ASTX660, SBP-0636457, JP1201, AZD5582, and BI 891065 and the immune checkpoint inhibitor is preferably selected from the group consisting of CTLA-4 antagonists, PD-1 inhibitors, LAG-3 inhibitors, TIGIT inhibitors, Tim-3 inhibitors and PDL-1 inhibitors.
Dependencies are inferred from the claim text.